Our data suggest that mitochondrial metabolism can be exploited by targeting the DYNLT1-Parkin-VDAC1 axis to further improve the ability of metabolic inhibitors to suppress breast cancers with limited treatment options, such as TNBC, in the future. The gene discussed is DYNLT1; the disease is breast cancer.